The ChadTough Foundation, The Michael Mosier Defeat DIPG Foundation and Dragon Master Foundation, along with its chapters and partner families, has made a grant of $250,000 to support the opening of a new Expanded Access Program for ONC201, an experimental drug currently being tested to treat DIPG. Expanded access is a mechanism for patients to access this experimental therapy when the patient is unable to participate in a clinical trial and meets eligibility criteria.

Oncoceutics has issued the following press release to announce the grant.

Oncoceutics Receives Grant to Establish an Expanded Acess Program for ONC201_updated 10.30